QCIG
HZNP

Quad-Cities Investment Group’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Quad-Cities Investment Group’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-2,000
Closed -$40K – 889
2018
Q3 		$40K Hold
2,000
– – 0.04% 395
2018
Q2 		$34K Buy
+2,000
New +$30.5K 0.03% 424

Other funds holding HZNP

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Quad-Cities Investment Group's HZNP Position: Q4 2018 in Review

Quad-Cities Investment Group sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2018, closing a stake of 2,000 shares — an estimated $40K sold.

Quad-Cities Investment Group first reported a position in HZNP in Q2 2018 and held it in 2 quarters. The position peaked at $40K in Q3 2018. 239 funds tracked by Wall St. Rank hold HZNP as of Q4 2018.

  • Quad-Cities Investment Group reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2018 after selling out during the quarter.
  • Quad-Cities Investment Group sold 2,000 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2018, an estimated $40K.
  • Quad-Cities Investment Group first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q2 2018 and held it in 2 quarters.
  • Quad-Cities Investment Group's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $40K in Q3 2018.
  • 239 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2018.

Based on Quad-Cities Investment Group's 13F filing for Q4 2018, filed 6 Feb 2019.